Design Therapeutics recently released its 10-Q report. The Carlsbad, California-based company is a clinical-stage biopharmaceutical firm founded in 2017 that is developing small-molecule GeneTAC® candidates for inherited nucleotide repeat expansion diseases. Its programs include Friedreich ataxia, myotonic dystrophy type 1, Fuchs endothelial corneal dystrophy and Huntington’s disease.
In Item 2, Management’s Discussion and Analysis, the company said it had cash, cash equivalents and investment securities of $207.4 million as of June 30, 2026, alongside an accumulated deficit of $334.8 million. It also said it has never generated revenue from product sales and has incurred net losses and negative operating cash flows since inception.
Design Therapeutics said its lead Friedreich ataxia program, DT-216P2, advanced through a Phase 1/2 RESTORE-FA trial. In May 2026, it reported four-week IV cohort data showing mean improvements from baseline of 6.4 points on mFARS, 2.7 points on upright stability score and more than five points on PROMIS Fatigue at the 1 mpk dose in four patients. The company also reported a 65% increase in whole blood FXN mRNA from baseline after four weeks at 1 mpk, a 22% to 27% increase in FXN-M and FXN-E protein two weeks after the last dose, and a 42% increase in muscle FXN mRNA.
The company said DT-216P2 was generally well tolerated, with no serious adverse events or treatment discontinuations. Mild to moderate transient ALT elevations were reported in three patients, with no associated bilirubin increases and all on background omaveloxolone.
Based on those data, Design Therapeutics said it is modifying the RESTORE-FA study to keep 1 mpk as the planned go-forward dose, enroll 10 patients in a 12-week cohort with planned duration extension, set endogenous blood FXN protein percent change from baseline as the primary efficacy endpoint, and explore a dose above 1 mpk. It expects an update on registrational plans in the fourth quarter of 2026 and 12-week data in the first quarter of 2027.
For DT-168, its Fuchs endothelial corneal dystrophy program, the company said it completed enrollment in an observational study of about 250 patients and selected about 100 for future follow-up visits. It also said a Phase 2 biomarker trial of DT-168 in corneal transplant patients has been delayed, with data now expected in 2027 because of a supply delay for blow-fill-seal eye droppers.
For DT-818, the myotonic dystrophy type 1 candidate, Design Therapeutics said it initiated dosing in a Phase 1 multiple-ascending-dose trial in the first half of 2026 and expects data in 2027. In preclinical work, it said DT-818 reduced toxic RNA foci by more than 90% in patient cells and improved myotonia in the HSALR mouse model.
For Huntington’s disease, the company said preclinical candidates reduced mutant huntingtin mRNA and protein by more than 50% in the brain striatum of zQ175DN mice after eight weeks of systemic dosing, while preserving wild-type huntingtin. Following these announcements, the company's shares moved 2.65%, and are now trading at a price of $12.5026. Check out the company's full 10-Q submission here.
